Fig. 1From: Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in SpainModel structure and transitions. PFS progression-free survival, PPS post-progression stateBack to article page